Purpose {#S0001}
=======

Breast cancer is the most frequently detected cancer in women in developed countries and its incidence ranges from 25% to 30% of all cancers in women. Average age of breast cancer patients range between 45 and 65, however, in recent years is noticeable that the average age of incidence tend to lower \[[@CIT0001]\]. With the prevalence of screening and increasing awareness of the disease, more and more women may be treated with breast-conserving surgery (BCS) with a complementary external beam radiation therapy (EBRT) and tumor\'s bed dose increasing ('boost'). Results of conservative treatment supplemented by radiation therapy are as good as the results obtained after mastectomy \[[@CIT0002]--[@CIT0006]\]. Further advances in radiotherapy techniques and knowledge of the biology of breast cancer, in addition to the standard methods of combination therapy (WBRT and 'boost'), increases the application of APBI as a radical treatment in particular cases \[[@CIT0007]--[@CIT0011]\]. This method of radiation therapy is used in a selected group of patients in the early stages of the disease \[[@CIT0003], [@CIT0012]--[@CIT0017]\]. The main reason for APBI introduction was the assumption that it leads to obtain an equivalent local control rates with less toxicity of treatment compared with whole breast irradiation technique (EBRT) after BCS in the selected group of patients. The results of studies comparing the effectiveness of BCS + WBRT and APBI have shown that a very large percentage of local recurrence (more than 80-90%) occurs in the immediate vicinity of the original location of the tumor.

This was the primary cause for the use of brachytherapy alone after breast-conserving therapy in a strictly selected group of patients. The advantage of this method is also shorter time of treatment from 5-7 weeks (WBRT + boost), to 4-5 days of APBI. It is supposed to be capable of reducing the rate of complications: radiation-induced reactions, telangiectasia and fibrosis. Due to increasing use of APBI methods we present the most recent reports on this subject. We describe the treatment techniques, principles of patient selection for this method, the results of treatment and current recommendations of GEC-ESTRO (Groupe Européen de Curietherapie -- European Society for Therapeutic Radiology and Oncology), ABS (American Brachytherapy Society) and ASTRO (American Society for Therapeutic Radiology), three major world societies of radiation oncologists.

Rationale for use of APBI {#S0002}
=========================

The results of studies examining the efficacy of BCS followed by whole breast radiotherapy (WBRT) showed that a very large percentage of local recurrence arises in the immediate vicinity of the original location of the tumor ([Fig. 1](#F0001){ref-type="fig"}). At least five prospective randomized studies examining the percentage of local recurrence after radiotherapy the whole breast were published and it was found that 69% to 90% recurrences occur in immediate vicinity of the primary tumor ([Table 1](#T0001){ref-type="table"}). In other studies, the percentage of recurrences in other quadrants than in being treated or contralateral breast was 0.9% to 3.5% in prospective studies and 2% to 5% in retrospective studies ([Table 2](#T0002){ref-type="table"}). This was the basic cause for the use of brachytherapy alone after BCS treatment in a strictly selected group of patients \[[@CIT0005], [@CIT0010], [@CIT0015], [@CIT0026]--[@CIT0028]\]. Another advantage of this method pointed out by many authors is also shortening the treatment duration from 5-7 weeks (conventional EBRT) to 4-5 days, what, particularly for working women, living far away from the cancer center and older patients is important. Offeresen *et al*. \[[@CIT0029]\] in the summary pointed out that in the U.S. socio-economic factors affect the type of surgery -- poorer women (eg, paying a lower insurance premium) and/or living far from the radiotherapy center choose mastectomy, even after qualifying for the BCS. In some areas, up to 25% of older women after BCS are not irradiated from these reasons. After examination of 175 000 patients with early breast cancer (SEER database) it was found that in 1992-2003 the percentage of BCS increased from 41% to 60%, while the proportion of patients irradiated after BCS decreased from 79% to 71%. Undoubtedly it affects the increased risk of local recurrences after BCS. Similar conclusions were reached by Njeh *et al*. \[[@CIT0030]\] -- in this article, they exchanged the factors affecting to decide RT: convenience, accessibility, cost, distance from the center of RT, lack of transportation, lack of social support, movement difficulties of patients doctor bias, age of the patient and fear of radiation. Also in Japan, only about 70% of patients are treated with radiotherapy after BCS, for similar reasons as in the U.S.

![Schematic location of the satellite foci of cancer in the immediate vicinity of the primary tumor](JCB-4-19362-g001){#F0001}

###### 

Spatial pattern of ipsilateral breast relapse (IBTR) in patients enrolled in randomised trials testing the effect of whole breast radiotherapy \[[@CIT0011]\]

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial (time of primary treatment)                            Median follow-up (range)   Recurrence number/ Total number of patients   Pattern of IBTR
  ------------------------------------------------------------ -------------------------- --------------------------------------------- -------------------------------------------------------------
  NSABP B-06 (1976-1984) \[[@CIT0012]\]                        39 (5-95) months           110 (1108)                                    86% within or close to the quadrant of the index cancer\
                                                                                                                                        14% more diffuse within the breast

  Uppsala-Orebro (1981-1988) \[[@CIT0013]\]                    10 years                   57 (381)                                      69% in the surgical field\
                                                                                                                                        3.6% in the cuticular scar\
                                                                                                                                        3.6% in the skin overlying the surgical field\
                                                                                                                                        23.6% in the breast parenchyma outside the field of surgery

  Ontario Clinical Oncology Group (1984-1989) \[[@CIT0014]\]   43 months                  131 (837)                                     86% (83% with RT) at the site of primary surgery

  Milan III (1987-1989) \[[@CIT0015]\]                         9 years                    75 (579)                                      85% (84% with RT) in the scar area\
                                                                                                                                        15% (16% with RT) in other quadrants

  SweBCG 91-RT (1991-1997) \[[@CIT0016]\]                      5 years                    104 (1178)                                    90% in the same quadrant as the previous tumour\
                                                                                                                                        10% in other quadrants
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Spatial pattern of ipsilateral breast relapse (IBTR) in patients treated with breast conserving surgery plus whole breast radiotherapy \[[@CIT0011]\]

  Authors, studies                      Median follow-up (range)              Local recurrence rate (%)   Recurrence rate outside of treated quadrant (%)   Recurrence rate in second breast (%)
  ------------------------------------- ------------------------------------- --------------------------- ------------------------------------------------- --------------------------------------
  Kurtz *et al*. \[[@CIT0017]\]         11 (5-24) years                       11                          2                                                 6
  Freedman *et al*. \[[@CIT0018]\]      5 years                               3                           1                                                 3
                                        10 years                              7                           2                                                 7
                                        15 years                              13                          6                                                 13
  Krauss *et al*. \[[@CIT0019]\]        5 years                               2                           0.1                                               4
                                        10 years                              7                           2                                                 9
                                        15 years                              10                          3                                                 12
  Veronesi *et al*. \[[@CIT0020]\]      8.5 years                             6.8                         1.4                                               5
                                        **Prospective trials (BCS + EBRT)**                                                                                 
  NSABP B-06 \[[@CIT0021]\]             39 (5-95) months                      2.7                         0.7                                               9.4
  Uppsala-Orebro trial \[[@CIT0013]\]   10 years                              8.5                         2.1                                               10.5
  Scottish trial \[[@CIT0022]\]         5.7 years                             5.8                         1.4                                               1
  Milan III \[[@CIT0015]\]              9 years                               5.4                         1.3                                               3.4
  NSABP B-21 \[[@CIT0023]\]             8 years                               9.3                         2.3                                               5.4
  SweBCG 91-RT \[[@CIT0016]\]           61 (10-98) months                     4.4                         1.1                                               3.4
  GBCSG trial \[[@CIT0024]\]            5.9 years                             4.2                         1                                                 2.1
  ABCSG study 8 \[[@CIT0025]\]          53.8 months                           0.5                         0.1                                               0.5

BCS -- Breast Conserving Surgery, EBRT -- External Beam Radiation Therapy

Indications for APBI {#S0003}
====================

Recommendations of the American Brachytherapy Society (ABS) and the American Society of Breast Surgeons (ASBS) on the qualifications for APBI are shown in [Table 3](#T0003){ref-type="table"} \[[@CIT0031]\], while the GEC-ESTRO (Groupe Européen de Curiethérapie European Society for Therapeutic Radiology and Oncology) recommendations are posted in [Table 4](#T0004){ref-type="table"} \[[@CIT0032]\].

###### 

American Brachytherapy Society and American Society of Breast Surgeons selection criteria and the Eligibility Criteria for NSABP B-39/RTOG 0413 Trial \[[@CIT0031]\]

                                       ABS                                ASBS                             NSABP B-39 RTOG 0413
  ------------------------------------ ---------------------------------- -------------------------------- ---------------------------------
  **Age**                              ≥ 50                               ≥ 45                             ≥ 18
  **Histology**                        unifocal, invasive ductal cancer   invasive ductal cancer or DCIS   invasive adenocarcinoma or DCIS
  **Tumor size**                       ≤ 3 cm                             ≤ 3 cm                           ≤ 3 cm
  **Surgical margins**                 negative microscopic margins       negative microscopic margins     negative microscopic margins
  **Number of involved lymph nodes**   0                                  0                                0--3

###### 

GEC-ESTRO recommendations on patient selection for accelerated partial-breast irradiation \[[@CIT0032]\]

  Characteristic             A\) Low-risk group -- good candidates for APBI         B\) Intermediate-risk group -- possible candidates for APBI   C\) High-risk group -- contraindication for APBI
  -------------------------- ------------------------------------------------------ ------------------------------------------------------------- --------------------------------------------------
  Age                        \> 50 years                                            40-50 years                                                   \< 40 years
  Histology                  IDC, mucinous, tubular, medullary, and colloid cc.     IDC, ILC, mucinous, tubular,medullary, and colloid cc         --
  ILC                        not allowed                                            not allowed                                                   --
  Associated LCIS            allowed                                                allowed                                                       --
  DCIS                       not allowed                                            allowed                                                       --
  HG                         any                                                    any                                                           --
  Tumour size                pT1-2 (\< 30 mm)                                       pT1-2 (\< 30 mm)                                              pT2 (\> 30 mm), pT3, T4
  Surgical margin            negative (\> 2 mm)                                     negative, but close (\< 2 mm)                                 positive
  Multicentricity            unicentric                                             unicentric                                                    multicentric
  Multifocality              unifocal                                               multifocal (limited within 2 cm of the index lesion)          multifocal (\> 2 cm from the index lesion)
  EIC                        not allowed                                            not allowed                                                   present
  LVI                        not allowed                                            not allowed                                                   present
  ER, PR status              any                                                    any                                                           --
  Nodal status               pN0 (SLNB or ALND[\*](#TF0001){ref-type="table-fn"})   pN1mi, pN1a (by ALND[\*](#TF0001){ref-type="table-fn"})       pNx; PpN2a (4 or more positive nodes)
  Neoadjuvant chemotherapy   not allowed                                            not allowed                                                   if used

APBI -- accelerated partial-breast irradiation; IDC -- invasive ductal carcinoma; ILC -- invasive lobular carcinoma; LCIS -- lobular carcinoma in situ; DCIS -- ductal carcinoma in situ; HG -- histologic grade; EIC -- extensive intraductal component; LVI -- lympho-vascular invasion; ER -- estrogen receptor; PR -- progesterone receptor; SLNB -- sentinel lymph node biopsy

ALND -- axillary lymph node dissection (at least 6 nodes pathologically examined)

Contraindications for APBI {#S0004}
==========================

It lists: clinical stage III or IV, no evaluation of surgical margins, presence of extensive intraductal component (EIC), Paget\'s disease, infiltration or other changes in skin, present contralateral breast cancer (or in the past), previous others cancers (within 5 years from eligibility for the study) with the exception of skin cancer and 0 or I stage FIGO cervical cancer (previous), pregnancy or lactation period, connective tissue disorders, collagen diseases, genetic or metabolic proceeding with hypersensitivity to radiation such as Ataxia teleangiectasia or similar, disorder or mental diseases, anticipated difficulties with carrying out brachytherapy \[[@CIT0003], [@CIT0006], [@CIT0010], [@CIT0011]\].

APBI techniques {#S0005}
===============

In APBI currently are applied several techniques: 1) Interstitial brachytherapy (HDR, PDR, permanent implants); 2) Brachytherapy using the balloons (Mammosite, Contura,); 3) Hybrid brachytherapy devices (SAVI applicator); 4) External beam radiotherapy (3D, IMRT); 5) IORT (intraoperative radiotherapy) with electrons or X-rays. Below we will discuss the basic principles of brachytherapy techniques.

Patient qualification for brachytherapy techniques {#S0006}
==================================================

Before preparing the treatment plan, a careful evaluation of tumor size and location should be made (clinical examination, mammography, ultrasonography (US), magnetic resonance (MRI)), determination of the stage of disease according to TNM and detailed histopathological examination should be performed. In the course of conservative treatment it is advisable to leave 4 to 6 clips on the border of tissue removed in the axis of anterior-posterior, posterio-medial, sagittal, up and down, which will facilitate the preparation of the brachytherapy treatment plan. Clipping of tumor bed is considered by many authors as the most precise factor determining the accuracy of brachytherapy. In the treatment planning using BT are also helpful: description of surgical procedures specifying the location of the scar in relation to the tumor bed, postoperative mammography, occasionally X-ray image of the tumor bed or postoperative ultrasound.

Interstitial multicatheter brachytherapy {#S20007}
----------------------------------------

Currently, two brachytherapy techniques are used in breast cancer brachytherapy: HDR (high dose rate) and PDR (pulsed dose rate). Some clinical studies are published on using permanent implants (I^125^, Pd^103^) \[[@CIT0033], [@CIT0034]\].

Techniques {#S20008}
----------

### Perioperative application of catheters

Brachytherapy using interstitial applicators can be performed in two ways. Perioperative brachytherapy involves the assumption of flexible applicators during surgery in place of the tumor bed. In this method, BT is applied immediately during BCS. The advantage of a perioperative technique is a need for only one general anesthesia (implantation of applicators takes place during surgery), resulting in reducing overall treatment time and the ability to precisely determining the location of the tumor visible during surgery. Throughout lumpectomy/quadrantectomy, the surgeon provides surgical clips (should be 6) to determine the tumor bed (the clips are helpful later in treatment planning). Applying of applicators requires precision, experience and basic knowledge in the field of radiation from the surgeon. The limitation of perioperative "boost" is the lack of the final histopathological examination-the risk of incorrect BT qualification can be leveled by precise clinical staging before procedure, intraoperative histological examination and the necessary implementation of the Sentinel-Lymph-Node Biopsy (SNL). The irradiated area is limited to the surgical bed with 1-1.5 cm margin depending on technique.

### Application of catheters after BCS

Applicators are often implanted after healing of the surgical scar and after receiving the final histopathological diagnosis in 2-4 weeks after surgery. Radiation oncologist inserts applicators after visualization of the tumor bed using X-ray (the location of surgical clips) and ultrasound (in general) or local anesthesia (depending on the experience of the center). Location of applicators on the skin with subcutaneous tissue and part of the breast is anesthetized with lidocaine or Xylocaine (2%) solution, while analgesics are intravenously administered. General anesthesia involves standard procedures. After determining the shape and position of the tumor bed, the correct template and number of planes is selected, as well as the distance between the applicators and the active length for stepping source. The number of implanted applicators has to be determined individually, depending on breast size, location of the tumor bed and type of surgery (tumorectomy, quadrantectomy). Frequently it is from 7 to over a dozen. [Figure 2](#F0002){ref-type="fig"} shows images of applicators implanted in a patient with breast cancer after quadrantectomy, covering the upper external quadrant. [Figures 3](#F0003){ref-type="fig"}-[5](#F0005){ref-type="fig"} present examples of treatment plan and applicators used in interstitial BT.

![Interstitial brachytherapy for breast cancer -- implantation of 7 flexible applicators attached to the skin with buttons, the tumor bed localized by ultrasound](JCB-4-19362-g002){#F0002}

![Example of 3D treatment plan for breast cancer, indicating target, applicators, and critical organs (plan prepared by Oncentra Prostate^®^)](JCB-4-19362-g003){#F0003}

![The distribution of dose (isodoses) obtained after the preparation of the treatment plan, target CT cross-sections performed every 2-3 mm](JCB-4-19362-g004){#F0004}

![Examples of applicators used in interstitial brachytherapy, A) from Varian Medical Systems (Breast Catheter Kits), B) from Nucletron Applicator Guide (Breast Template Set "Rabbit")](JCB-4-19362-g005){#F0005}

Balloon brachytherapy (MammoSite, Contura) and hybrid SAVI applicators {#S20011}
----------------------------------------------------------------------

This technique was intended to reduce the technical difficulties associated with EBRT treatment planning and application of many interstitial applicators. The balloon applicator consists of a silicone balloon catheter, containing a channel for filling the balloon and 1 to 8 channels to introduce radioisotope ([Figs. 6A](#F0006){ref-type="fig"}-[B](#F0006){ref-type="fig"}, [7A](#F0007){ref-type="fig"}-[B](#F0007){ref-type="fig"}). SAVI applicator does not include a balloon, but only applicators to adapt to the shape of the box ([Figs. 8A](#F0008){ref-type="fig"}-[D](#F0008){ref-type="fig"}). Balloon technique in principle is applicable in APBI without WBRT after surgery. HDR sources are used in this technique. Balloon applicators may be placed in the bed of the tumor during the BCS (rarely) or 2-4 weeks after surgery with the help of ultrasound. Previously published results suggest a satisfactory treatment outcome (as measured by the percentage of local failure) and good cosmetic results (80% to 93% of patients) \[[@CIT0036]--[@CIT0043]\]. So far, we do not have randomized studies comparing this technique treatment with interstitial BT. The possible response will bring the results of Phase III Trial (NSABP B-39/RTOG 0413) conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the Radiation Therapy Oncology Group (RTOG). The objective of this trial is to compare the results of different treatment methods: WBRT, APBI with MammoSite or multicatheter interstitial BT 3D EBRT in stage 0, I and II of breast cancer \[[@CIT0038]\].

![A) MammoSite device used in balloon brachytherapy (Hologic^®^, Marlborough). B) MammoSite balloon applicator in CT cross section with the indication of lung](JCB-4-19362-g006){#F0006}

![A) Contura balloon applicator (SenoRx^®^) \[[@CIT0030]\]. B) Contura balloon applicator on CT section with the distribution of isodoses, 5 channels for iridium visible](JCB-4-19362-g007){#F0007}

![A) Applicator SAVI (Strut Adjusted Volume Implant) with expanded channels (Cianna Medical^®^) \[[@CIT0030]\]. B) SAVI applicator X-ray images showing surgical clips (arrows) \[[@CIT0035]\]. C) SAVI applicator, a balloon with a visible isodoses \[[@CIT0035]\]](JCB-4-19362-g008){#F0008}

Balloon brachytherapy was developed as an alternative to interstitial brachytherapy. Interstitial brachytherapy requires the experience in setting up many interstitial applicators, while using balloon brachytherapy is simpler in the application. Cosmetic results after balloon brachytherapy techniques seem to be very acceptable \[[@CIT0037], [@CIT0040], [@CIT0043]--[@CIT0045]\] with a high rate of satisfactory or excellent results. To achieve such results, the proper selection of patients (large breasts, central location of the primary tumor) is significant.

Technique {#S20012}
---------

The balloon applicator consists of a silicone balloon with catheter to fill the balloon with fluid and 1 to 8 channels, where a radioactive source is placed. For the greater precision, in most centers using this method, the balloon is fixed in the operating room under ultrasonography. Then the applicator is fluid-filled to a volume strictly adhering to the walls of the tumor bed. Afterwards, a cross-section CT is made in order to prepare a treatment plan. Target (CTV) includes the volume of the balloon with a margin of 1 cm. Critical organs include the skin and lungs. In this technique HDR sources are used.

Doses {#S20013}
-----

The most common treatment schemas of APBI techniques are: 1) fraction dose of 3.4 Gy two times daily with an interval of 6 hours, 10 fractions in 5 days to a total dose of 34 Gy; 2) fraction dose of 4 Gy two times daily -- 8 fractions to 32 Gy; 3) fraction dose of 4.3 Gy two times daily -- 7 fractions to 30.1 Gy \[[@CIT0031], [@CIT0032]\].

Electronic brachytherapy \[[@CIT0030]\] {#S20014}
---------------------------------------

A platform for delivering HDR brachytherapy radiation has been developed that involves the electronic generation of kV X-rays instead of using a radioactive source. The Axxent X-Ray Source manufactured by Xoft, Inc. was approved by the FDA for the treatment of breast cancer in January 2006 ([Figs. 9A](#F0009){ref-type="fig"}-[C](#F0009){ref-type="fig"}). The Xoft Axxent produces X-rays ranging from 20 to 50 kV, although only the 50 kV X-ray setting is used in breast brachytherapy. Using the 50 kV setting, the average energy of the X-rays is 28 keV; the radial dose function lies between those of ^125^I and ^103^Pd sources \[[@CIT0046]\]. The Xoft Axxent Electronic Brachytherapy source is used in conjunction with a balloon applicator. The disposable source is intended to be used for a maximum of 10 fractions. Testing of the inter-source consistency performed by Rivard *et al*. shows that individual sources produce predictable energy spectra, anisotropy functions and radial dose functions. As such, independent dosimetric verification is not necessary for each source. Instead, prior to each treatment, a single measurement of the source air-kerma strength is the only requirement \[[@CIT0046]\].

![Example of 3D treatment plan for breast cancer, indicating target, applicators, and critical organs (plan prepared by Oncentra Prostate^®^) A) Axxent Electronic Brachytherapy System, the control unit (Xoft^®^) \[[@CIT0030]\]. B) Axxent Electronic Brachytherapy System, X-ray source HDR (Xoft^®^) \[[@CIT0030]\]. C) Axxent Electronic Brachytherapy System, a balloon applicator (Xoft^®^) \[[@CIT0030]\]](JCB-4-19362-g009){#F0009}

The low energy photons emitted from the kV brachytherapy source (KVB) have a limited range that obviates the need for a shielded radiation vault. This expands the settings in which the source could be used and may increase the availability of PBI. Additionally, the difference in photon energy between a KVB source and an ^192^Ir source has dosimetric implications. Dickler *et al*. found that the %V90 and %V100 do not appear to differ between KVB and MammoSite, demonstrating that KVB offers comparable target volume coverage. Due to its rapid dose fall-off, KVB provides a mean ipsilateral lung %V30 of 1.1% compared to 3.7% for MammoSite. Using KVB, the volume of the PTV receiving 200% of the prescription dose slightly exceeded the volume associated with an increased risk of fat necrosis in a previous study by Wazer *et al*. \[[@CIT0044]\]. Similarly, a phantom study of KVB by Smitt *et al*. found that in order to achieve 90% coverage of the PTV, the V200 varied from 16 to 22 cm^3^ \[[@CIT0048]\]. These figures are far higher than those of MammoSite and approach the dose-volume constraints that have been shown to be correlated with fat necrosis in studies of interstitial multicatheter brachytherapy \[[@CIT0049]\]. However, it is unclear if dosimetric parameters that predict fat necrosis in multicatheter procedures are applicable to balloon applicator procedures. The effect of chemotherapy on the development of fat necrosis also remains to be clarified.

Results of APBI {#S0015}
===============

Comparison of different APBI techniques is posted in [Table 5](#T0005){ref-type="table"} \[[@CIT0029], [@CIT0050]\]. Clinical results of APBI after various treatment techniques are presented in tables. [Table 6](#T0006){ref-type="table"} presents the results of interstitial brachytherapy, [Tables 7](#T0007){ref-type="table"}, [8](#T0008){ref-type="table"} -- results of balloon brachytherapy.

###### 

Comparison of APBI techniques -- from Offersen \[[@CIT0029]\] and Sarin \[[@CIT0050]\]

                                                                        3D EBRT                                                        Interstitial brachytherapy HDR, LDR, PDR                           MammoSite                                                                                      Targit, 50 kV X-rays                                                               IORT, electrons
  --------------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------ ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  Coverage of target                                                    best                                                           good                                                               good                                                                                           good                                                                               good
  Thickness of cavity wall irradiated                                   PTV = tumor bed + 20-25 mm often 5 mm to field edge from PTV   1-2 cm                                                             dose prescribed to 1 cm from surface of applicator                                             dose prescribed to 1 mm from surface of applicator. 5-7 Gy 10 mm from applicator   dose prescribed to 90% isodose line. 80% isodose at 13 mm (3 MeV) -- 24 mm (9 MeV)
  Dose                                                                  best                                                           fair                                                               fair                                                                                           fair                                                                               fair
  homogeneity                                                                                                                                                                                                                                                                                                                                                                               
  Sparing of normal breast/ other organs                                least                                                          good                                                               good                                                                                           best                                                                               varies with location
  Skin dose                                                             least                                                          least                                                              variable                                                                                       least (can shield)                                                                 least
  Technical feasibility for various size, shape or location of cavity   suitable for virtually all cases                               not suitable if inadequate tissue or near axilla                   not suitable for large/irregular cavities, or at the periphery of the breast                   not suitable for large/irregular cavities, or at the periphery of the breast       not suitable for tumors near brachial lexus/axilla or skin
  Expertise required                                                    average                                                        high                                                               average                                                                                        high                                                                               very high
  Potential for wide spread use                                         very good                                                      fair                                                               very good                                                                                      fair                                                                               limited
  Main drawback                                                         relatively higher dose to normal tissue and breathing motion   adequacy of target overage in some cases and wider applicability   cavity shape and size. Although easy to use, stringent QA is required. Skin dose may be high   very limited depth irradiated; cavity shape and size, histology not available      wider applicability. Histology not available, based on quadrantec-tomy

###### 

Results of recent clinical experience with interstitial brachytherapy with more than 5 years follow-up \[[@CIT0030]\]

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                              No of cases   Follow up interval (years)   Technique   Scheme                     Total dose (Gy)   5-year LR (%)   Good/Excellent cosmesis
  ----------------------------------- ------------- ---------------------------- ----------- -------------------------- ----------------- --------------- -------------------------
  Strnad *et al*. \[[@CIT0051]\]      274           5.25                         PDR/HDR     PDR -- 0.6 Gy/h\           PDR = 50 Gy\      2.9%            90%
                                                                                             HDR -- 4 Gy × 8 fr.        HDR = 32 Gy                       

  Antonucci *et al*. \[[@CIT0052]\]   199           9.6                          LDR/HDR     LDR -- 0.52 Gy/h × 96 h\   LDR = 50 Gy\      5%              99%
                                                                                             HDR -- 4 Gy × 8 fr.\       HDR = 32 Gy\                      
                                                                                             HDR -- 3.4 Gy × 10 fr      HDR = 34 Gy                       

  Johansson *et al*. \[[@CIT0053]\]   50            7.2                          PDR         HDR -- 50 Gy/5 d           50 Gy             4%              56%

  Arthur *et al*. \[[@CIT0054]\]      99            7                            LDR/HDR     LDR -- 3.5 Gy/5 d\         45 Gy (LDR)\      4%              n/a
                                                                                             HDR -- 3.4 Gy × 10 fr.     34 Gy (HDR)                       

  Polgar *et al*. \[[@CIT0055]\]      128           6.8                          HDR         HDR -- 5.2 Gy × 7 fr.      36.4 Gy           4.7%            77%

  King *et al*. \[[@CIT0056]\]        51            6.25                         LDR/HDR     LDR -- 4 d\                45 Gy (LDR)\      3.9%            75%
                                                                                             HDR -- 4 Gy × 8 fr.        32 Gy (HDR)                       

  Otto *et al*. \[[@CIT0057]\]        274           5.25                         PDR/HDR     PDR -- 5 d, 0.6 Gy/h\      49.8 Gy (PDR)\    2.9%            92%
                                                                                             HDR -- 4 Gy × 8 fr.        32 Gy (HDR)                       

  Polgar *et al*. \[[@CIT0058]\]      45            11.1                         HDR         HDR -- 4.33 Gy × 7 fr.\    30.3 Gy\          4.4%            78%
                                                                                             HDR -- 5.2 Gy × 7 fr.      36.4 Gy                           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LR -- local recurrence; HDR -- high dose rate; LDR -- low dose rate; PDR -- pulsed dose rate; n/a -- data not available; h -- hours, d -- days; fr. -- fractions

###### 

Some of the recent clinical experience with MammoSite \[[@CIT0029]\]

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Institution                                                                                            APBI technique      No. Of cases       Follow-up (years)   Inclusion criteria and definition of target                                                                                             Ipsilateral breast recurrence
  ------------------------------------------------------------------------------------------------------ ------------------- ------------------ ------------------- --------------------------------------------------------------------------------------------------------------------------------------- -------------------------------
  American Society of Breast Surgeons, MammoSite Breast Brachytherapy Trial \[[@CIT0059]--[@CIT0064]\]   34 Gy/10 fr/5 d     1255               2.5                 \> 45 years, T6 2 cm, N0, negative margins, ductal only, applicator\                                                                    2 years -- 1.11%,\
                                                                                                                                                                    placement \< 10 weeks postoperative, cavityP3 cm in one dimension, no EIC,                                                              3 years -- 1.79%

  Texas Cancer Clinic San Antonio \[[@CIT0065]\]                                                         34 Gy/10 fr/5-7 d   67                 1.1                 ≥ 45 years, T \< 3 cm, N0, negative margins, lumpectomy cavity 3-6 cm                                                                   NA

  Kaiser Pernamente Los Angeles Medical Center \[[@CIT0066], [@CIT0067]\]                                34 Gy/10 fr/5-7 d   51                 1.3                 ≥ 45 years, T6 2 cm, N0, ductal only, negative margins                                                                                  0

  Rush University Medical Center, Chicago \[[@CIT0068], [@CIT0069]\]                                     34 Gy/10 fr/5-7 d   78                 2.2                 ≥ 45 years, T \< 3 cm, N0, negative margins                                                                                             7.1%

  Medical University of South Carolina \[[@CIT0070]\]                                                    32 Gy/10 fr/5-7 d   37 (7 with DCIS)   0.5                 any age, pTis-pT2N1, negative margins                                                                                                   NA

  Tufts New England \[[@CIT0071], [@CIT0072]\]                                                           34 Gy/10 fr/5-7 d   38                 1.4                 any age, T \< 3 cm, ductal and DCIS, N0 (solitary nodal micrometastasis accepted), negative margins \> 1 mm                             NA

  European MammoSite trial \[[@CIT0073], [@CIT0074]\]                                                    34 Gy/10 fr/5-7 d   28                 1.2                 ≥ 60 years, T ≤ 2 cm, ductal only, grade 1/2, margins \> 5 mm, ER +, balloon-skin distance \> 7 mm, lumpectomy cavity \> 3 cm, no EIC   0
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EIC -- extensive intraductal component; DCIS -- ductal carcinoma in situ; ER -- estrogen receptor; PR -- progesterone receptor; N/A -- data not available; d -- days; fr -- fractions

###### 

Local recurrences after MammoSite \[[@CIT0031]\]

  Trial                                                        No. of cases   Follow-up (months)   Local recurrences rate (%)
  ------------------------------------------------------------ -------------- -------------------- ----------------------------
  ASBS TRIAL \[[@CIT0075]\]                                    1440           30                   1.04
  Tufts/Medical College Virginia/Rhode Island \[[@CIT0071]\]   28             19                   0
  St. Vincent Cancer Center \[[@CIT0066]\]                     31             11                   0
  Rush University Medical Center \[[@CIT0076]\]                70             26                   5.7
  Kaiser Permanente \[[@CIT0049]\]                             40             13                   0
  Medical University South Carolina \[[@CIT0074]\]             90             24                   2.2
  ASBS DCIS TRIAL \[[@CIT0077]\]                               191            7                    0
  Wiliam Beaumont \[[@CIT0068]\]                               80             22                   2.5
  European TRIAL \[[@CIT0073]\]                                44             14                   0
  International TRIAL \[[@CIT0078]\]                           23             20                   0
  Western Pensylwania Hospital \[[@CIT0079]\]                  55             24                   3.6
  Oscar Lambret Center \[[@CIT0069]\]                          25             13                   0

Cosmetic effect {#S0016}
===============

Cosmetic results after brachytherapy techniques seem to be very satisfactory. Draws attention a high rate of satisfactory or excellent results. Essential to achieve such results is a proper selection of patients (large breasts, the central location of the primary tumor).

The tables below provide a summary of cosmetic results after using the balloon brachytherapy and interstitial brachytherapy ([Tables 9](#T0009){ref-type="table"} and [10](#T0010){ref-type="table"}).

###### 

Rates of good and excellent cosmesis after MammoSite brachytherapy \[[@CIT0031]\]

  Institution/Study                                               Number of patients   Follow-up (months)   Good or excellent cosmesis (%)
  --------------------------------------------------------------- -------------------- -------------------- --------------------------------
  ASBS registry trial \[[@CIT0063]\]                              1449                 30                   94
  FDA trial \[[@CIT0075]\]                                        36                   65                   81
  Tufts/medical college of Virginia/Rhode Island \[[@CIT0046]\]   28                   19                   93
  St. Vincent\'s cancer center \[[@CIT0066]\]                     31                   11                   86
  Rush university medical center \[[@CIT0076]\]                   30                   26                   93
  Kaiser permanente \[[@CIT0049]\]                                40                   13                   97
  Medical University of South Carolina \[[@CIT0074]\]             90                   24                   90
  ASBS DCIS trial \[[@CIT0077]\]                                  191                  7                    94
  William Beaumont \[[@CIT0068]\]                                 80                   22                   88
  European trial \[[@CIT0073]\]                                   44                   14                   75
  International trial \[[@CIT0078]\]                              18                   20                   67
  Oscar Lambret center \[[@CIT0069]\]                             25                   13                   84

###### 

Cosmesis and complications after APBI with interstitial brachytherapy \[[@CIT0029]\]

  Institution                                                                 Technique                                                                                               Number of patients   Follow-up                              Cosmesis and complications
  --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- -------------------- -------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The William Beaumont Hospital, USA \[[@CIT0049], [@CIT0080]--[@CIT0082]\]   HDR 32-34 Gy/8-10 fr/4-5 days LDR 50 Gy, 96 hours                                                       199                  5.7 years (LR), 6.4 years (cosmesis)   7% acute infection, 4% late infection, 11% fat necrosis at ≥ 5 years[a](#TF0002){ref-type="table-fn"}, good/excellent cosmesis[b](#TF0003){ref-type="table-fn"} in \> 90%
  Ochsner Clinic, USA \[[@CIT0083]\]                                          HDR 32-34 Gy/8-10 fr/ 4-5 days LDR 45 Gy, 4 days                                                        50                   6.3 years                              cosmesis scored at median 20 months: 22% grade I/II compl., 8% grade III compl., 75% had an excellent/ good cosmesis[a](#TF0002){ref-type="table-fn"}, all based on[a](#TF0002){ref-type="table-fn"}
  Ochsner Clinic, USA \[[@CIT0084]\]                                          HDR 32-34 Gy/8-10 fr/4-5 days LDR 45 Gy, 4 days                                                         99                   2.7 years                              late grade III tox. 18% (LDR) and 4% (HDR), no late grade IV tox., all based on[a](#TF0002){ref-type="table-fn"}
  London Regional Cancer Center, Ontario \[[@CIT0085]\]                       HDR 37.2 Gy/10 fr/5 days                                                                                39                   7.6 years                              median overall cosmetics score 89%, 13% had fat necrosis[a](#TF0002){ref-type="table-fn"}, all based on[a](#TF0002){ref-type="table-fn"}
  Tufts New England \[[@CIT0044], [@CIT0086]--[@CIT0088]\]                    HDR 34 Gy/10 fr/5 days                                                                                  75                   6.1 years                              cosmesis[a](#TF0002){ref-type="table-fn"}, excellent/good/fair-poor: 67%/24%/9% at last follow-up, late skin tox.[c](#TF0004){ref-type="table-fn"} grad. 1/2/3 77%, 19%, 4%, late subcutaneous tox. grad. 1/2/3/4 55%, 15%, 12%, 18%
  Tufts New England \[[@CIT0089]\]                                            LDR 50, 55, and 60 Gy                                                                                   48                   1.9 years                              very good/excellent cosmesis 91.8%, 12.5% perioperative complications, 25% had fibrosis, 8% moderate to severe fibrosis, based on[a](#TF0002){ref-type="table-fn"}
  Tufts New England \[[@CIT0090]\]                                            HDR 34 Gy/10 fr/5 days                                                                                  32                   7 years                                18% had fat necrosis \> 5 years, 35.7% moderate to severe subcutaneous fibrosis \> 5 years, 89% excellent cosmesis at 5 years, toxicity based onc, fibrosis \> 5 years
  University of Kansas \[[@CIT0091]\]                                         LDR 20-25 Gy                                                                                            24                   3.9 years                              cosmesis good to excellent in 100%, no late complications, based on[a](#TF0002){ref-type="table-fn"}
  Guys Hospital, London \[[@CIT0092], [@CIT0093]\]                            LDR 55 Gy, 5 days                                                                                       27                   6 years                                cosmesis good to excellent in 83%, no fibrosis, based on[a](#TF0002){ref-type="table-fn"}
  Guys Hospital, London \[[@CIT0094]\]                                        LDR 45 Gy, 4 days                                                                                       49                   6.3 years                              abnormal breast in 58%, based on[a](#TF0002){ref-type="table-fn"}
  National Institue of Oncology, Hungary \[[@CIT0095], [@CIT0096]\]           HDR 30.3-36.4 Gy/7 fr/4 days                                                                            45                   6.8 years                              cosmesis excellent/good in 84.4%, fat necrosis 20%, ≥ grade 2 late radiation reaction 26.7%, based on[b](#TF0003){ref-type="table-fn"}
  National Institue of Oncology, Hungary \[[@CIT0055], [@CIT0097]\]           HDR 36.4 Gy/7 fr/4 days (*n* = 88) or ERBT 50 Gy/25 fr (*n* = 40)                                       126                  5.5 years                              excellent to good in 81.2% (HDR) and 70% (electrons), based on[b](#TF0003){ref-type="table-fn"}, 4-year actuarial fat necrosis 36.5% (HDR) and 17.7% (electrons), based on institutional scheme
  Erlangen, Germany \[[@CIT0057], [@CIT0098]--[@CIT0100]\]                    HDR (36%) 32 Gy/8 fr/5 days; PDR (64%) 49.8 Gy in 83 consecutive fractions of 0.6 Gy each hour/5 days   274                  2.7 years                              cosmesis excellent to good in 94%, acute toxicity in 6.6%, fat necrosis 4.7%, breast tissue fibrosis in 19.3% and telangiec-tasia in 12.8%, scoring based on[b](#TF0003){ref-type="table-fn"}^,^[c](#TF0004){ref-type="table-fn"}^,^[d](#TF0005){ref-type="table-fn"}

Number of patients refers to patients diagnosed with invasive cancer

Cosmesis scored according to institutional guidelines

Cosmesis scored according to Harvard criteria \[[@CIT0101]\]

Skin and subcutaneous toxicity scored according to Radiation Therapy Oncology Group (RTOG)/Eastern Cooperative Oncology Group system \[[@CIT0102]\]

Acute and late side effects based on LENT SOMA \[[@CIT0103]\]

Conclusions {#S0017}
===========

The percentage of local recurrence and the cosmetic results are an important argument for the choice of APBI brachytherapy technique. Based on available results from prospective clinical trials where excellent results in selected groups of patients are achieved, it seems reasonable to use of APBI outside clinical trials in selected cases. These is a conclusion also of GEC-ESTRO Breast Cancer Working Group \[[@CIT0032]\]. Strict criteria for selecting patients with early breast cancer group (low-risk group) and systematic quality control procedures (QA) must be preserved. These recommendations may be an indication for physicians and patients to choose an APBI techniques.
